8-K: RYAM Q3: Mixed Results Amid Strategic Shift & Tariff Headwinds

Rayonier Advanced Materials reports a significant improvement in net loss for Q3 2025, despite a decline in net sales and adjusted EBITDA, as strategic biomaterials initiatives advance.

Summary

• Net sales for the third quarter of 2025 were $353 million, a decrease of $48 million from the prior year quarter.
• Loss from continuing operations for Q3 2025 improved to $4 million, a $29 million improvement from the $33 million loss in the prior year quarter.
• Adjusted EBITDA from continuing operations for Q3 2025 was $42 million, down $9 million from $51 million in the prior year quarter.
• Total Debt stood at $794 million and Net Secured Debt at $729 million as of September 27, 2025, with a covenant net secured leverage ratio of 4.1 times.
• Year-to-date Cash Used in Operating Activities was $(8) million, and Adjusted Free Cash Flow was $(83) million, partially due to working capital timing expected to improve in Q4.
• Full year 2025 Adjusted EBITDA is expected to approximate $135 million to $140 million, including a $12 million non-cash environmental charge from Q1.
• Adjusted Free Cash Flow is expected to approximate $25 million to $30 million in the fourth quarter, driven by improved working capital and stronger financial performance.
• The long-term strategy to achieve over $300 million in run-rate EBITDA by the end of 2027 remains firmly intact.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While Q3 2025 saw declines in net sales and adjusted EBITDA, and significant negative year-to-date cash flow, the net loss improved substantially. Management's forward guidance for Q4 free cash flow and long-term EBITDA targets is positive, and strategic biomaterials initiatives are progressing. However, ongoing market headwinds, tariff impacts, and delays in strategic asset sales temper the overall outlook.

Positives

• Loss from continuing operations improved significantly by $29 million year-over-year, from $33 million to $4 million.
• The core Cellulose Specialties business performed as expected, approaching normalized levels, with transitory pressures easing and signs of stabilization across demand, operational performance, and costs.
• Targeting a significant price reset for Cellulose Specialties in 2026, aiming to recapture value lost to inflation.
• The long-term strategy to deliver over $300 million in run-rate EBITDA by the end of 2027 remains firmly intact, supported by tangible progress across strategic pillars.
• Biomaterials execution is advancing, with projects expected to add approximately $31 million of run-rate proportional EBITDA exiting 2027.
• Structural cost reductions are targeting approximately $30 million in annual savings by 2026, with potential for up to $20 million of additional annual savings in 2027.
• A strong finish to 2025 is expected, with Q4 Adjusted Free Cash Flow projected to approximate $25 million to $30 million.
• The U.S. International Trade Commission (USITC) issued an affirmative injury determination in the high-purity dissolving pulp (HPDP) trade case, advancing the case.
• Biomaterials projects are progressing, including the operational bioethanol facility in France, the re-started lignosulfonate powder plant, and the purchase of high-quality crude tall oil (CTO) plant equipment for the Jesup CTO project.
• Received GRAS (generally recognized as safe) status for its prebiotics product from the U.S. Food and Drug Administration, with live animal tests showing over 2X greater efficacy versus an existing additive.
• Corporate operating loss improved by $4 million year-over-year due to lower variable compensation costs and favorable foreign exchange rates.

Negatives

• Net sales decreased by $48 million, or 12%, compared to the prior year quarter.
• Adjusted EBITDA from continuing operations decreased by $9 million year-over-year.
• Year-to-date Cash Used in Operating Activities was $(8) million, and Adjusted Free Cash Flow was $(83) million, indicating significant cash outflows.
• Cellulose Specialties sales volumes decreased 17% due to larger customer orders in the prior year, weaker demand, continued customer destocking in the acetate market, and ongoing global tariff impacts.
• Operational challenges, primarily at the Tartas cellulose plant, and French national labor strikes impacted Cellulose Specialties and Biomaterials production.
• Biomaterials operating income decreased $2 million, or 67%, due to higher shared and ancillary service costs under the new business structure.
• Cellulose Commodities operating loss increased $4 million compared to Q2 2025, driven by lower average sales price from weakening markets, China tariffs on fluff products, and increased volumes of negative margin sales.
• Paperboard net sales decreased $16 million, or 29%, due to mix, tariff uncertainty, increased European Union imports, and new U.S. competitor capacity, leading to a 157% decline in operating results.
• High-Yield Pulp net sales decreased $4 million, or 14%, due to lower demand (especially in China), continued oversupply in China, and shipping challenges to India, resulting in a 100% decline in operating results.
• Paperboard and High-Yield Pulp production lines are being idled for three weeks during the fourth quarter due to ongoing market weakness and softer sales outlook.
• Interest expense increased $5 million compared to the prior year quarter, primarily due to an increase in the average effective interest rate on debt.
• The process to explore a potential sale of the Paperboard and High-Yield Pulp businesses remains in flux due to current market dynamics, evolving trade conditions, and ongoing discussions related to the renewal of the USMCA in July 2026.
• The City of Fernandina Beach denied the site plan application for a potential bioethanol facility, requiring the Company to pursue administrative and legal avenues.
• Chinese retaliatory tariffs continue to disrupt global fluff market dynamics, leading to a shift in production toward non-fluff commodities.
• Corporate costs for full year 2025 are expected to be higher due to a $12 million non-cash environmental reserve charge in Q1 and potential continued foreign exchange headwinds.

Risks

• Disruptions in the global economy caused by geopolitical conflicts and related impacts.
• Highly competitive and cyclical businesses, leading to fluctuations in pricing and volume.
• Changes in the availability and price of raw materials and energy, and continued inflationary pressure.
• Material risks associated with doing business outside of the United States, including foreign currency exchange fluctuations.
• Restrictions on trade through tariffs, countervailing and anti-dumping duties, quotas, and other trade barriers.
• Risks associated with epidemics and pandemics.
• Reliance on ten largest customers for a significant portion of 2024 revenue.
• Material disruption at any manufacturing plant.
• Unfavorable changes in the availability of, and prices for, wood fiber.
• Substantial capital required to maintain production facilities, and the cost to repair or replace equipment.
• Risks to assets, including the potential for substantial impairment of long-lived assets.
• Requirement to recognize a significant non-cash charge to earnings if recorded deferred tax assets are deemed unrealizable.
• Dependence on third parties for transportation services.
• Failure to maintain satisfactory labor relations.
• Dependence on attracting and retaining key personnel.
• Failure to meet customer needs through new product development or inability to protect intellectual property.
• Loss of Company intellectual property and sensitive data or disruption of manufacturing operations due to a cybersecurity incident.
• Challenges and uncertainties in executing the Biomaterials strategy.
• Extensive environmental laws, regulations, and permits.
• Uncertain long-term impact of climate-related risks and regulatory measures to address climate change.
• Need for significant additional cash contributions to retirement benefit plans.
• Debt obligations that could materially adversely affect the business and its ability to meet obligations.
• Covenants in debt agreements may impair the ability to operate the business.
• Challenges in the commercial and credit environments affecting future access to capital.
• Need for additional financing in the future, which may not be available on favorable terms or may be dilutive to existing stockholders.
• Stockholders' ownership in RYAM may be diluted.
• Certain provisions in corporate documents and Delaware law could prevent or delay an acquisition of the Company.

Future Outlook

The Company anticipates a strong finish to 2025, with full-year Adjusted EBITDA projected between $135 million and $140 million, supported by stable Cellulose Specialties operations, improved order trends, and cost discipline. Adjusted Free Cash Flow for Q4 2025 is expected to be $25 million to $30 million, reflecting improved working capital and stronger financial performance. Looking ahead, the Company expects to more than double EBITDA over the next two years, driven by multi-year Cellulose Specialties price actions, efficiency gains, and structural cost reductions targeting $30 million in annual savings by 2026, with potential for an additional $20 million in 2027. Biomaterials projects are expected to add approximately $31 million of run-rate proportional EBITDA exiting 2027, reinforcing the long-term strategy to achieve over $300 million in run-rate EBITDA by the end of 2027, with further upside from the AGE project coming online in late 2028. Final investment decisions on Biomaterials projects are expected in 2025 and early 2026.

Management Comments

• "Our third quarter reflects the strength of our core business and the resilience of our teams executing through a dynamic backdrop."
• "The core Cellulose Specialties business performed as expected, approaching normalized levels. The transitory pressures we faced earlier in the year continue to ease, and were seeing clear signs of stabilization across demand, operational performance and costs."
• "As we kick off 2026 Cellulose Specialties pricing discussions, we are targeting a significant reset beyond prior year increases, reflecting the value of our products and recapturing value lost in prior years inflation."
• "We remain firmly committed to our roadmap to deliver over $300 million in run-rate EBITDA by the end of 2027. That conviction is grounded in tangible progress across our strategic pillars strengthening our Cellulose Specialties franchise, advancing Biomaterials execution and driving structural cost and mix improvements across our operations."
• "As we continue to normalize performance, we're maintaining a disciplined focus on cash management and liquidity. Our priorities remain clear maximize cash generation, manage working capital efficiently and preserve financial flexibility to support our long-term goals. We do not anticipate any issues with our covenants or liquidity and remain committed to prudent financial stewardship as we execute on our strategy and build durable value for our shareholders."

Industry Context

The company is navigating a challenging global environment marked by ongoing tariff impacts, particularly affecting the acetate market within Cellulose Specialties and the fluff market within Cellulose Commodities due to Chinese retaliatory tariffs. Increased competitive activity from European Union imports and new U.S. capacity is impacting the Paperboard segment, while oversupply in the Chinese market continues to depress High-Yield Pulp prices and demand. The company's proactive measures, such as idling production lines and shifting product mix, reflect broader industry efforts to manage supply in response to weakened demand. The pursuit of green energy and renewable products through its Biomaterials strategy aligns with a growing industry trend towards sustainability and diversification away from traditional pulp and paper products.

Comparison to Industry Standards

• The North American shipment to capacity ratio for Paperboard is below analysts' projections for 2025, indicating weaker market conditions than anticipated.
• Live animal tests of the company's prebiotics products showed over 2X greater efficacy versus an existing prebiotics additive, demonstrating superior product performance in a specific application.

Legal Proceedings

• RYAM and the United Steelworkers (USW) jointly filed petitions with the U.S. International Trade Commission (USITC) and the U.S. Department of Commerce (USDOC) alleging that Brazilian and Norwegian producers of high-purity dissolving pulp (HPDP) are selling into the U.S. market at unfairly low prices or with the benefit of government subsidies.
• The Company is pursuing available administrative and legal avenues after the City of Fernandina Beach denied its site plan application for a potential bioethanol facility.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic growth initiatives and cost reductions, but also risks from market volatility, debt obligations, and potential future dilution from financing.
• Employees: Impacted by production idling in the Paperboard and High-Yield Pulp segments during the fourth quarter.
• Customers: Affected by tariff impacts, customer destocking, and changes in demand, particularly in acetate and fluff markets.
• Suppliers: Potential impact from changes in raw material demand and pricing, as well as operational challenges at manufacturing plants.
• Regulatory Authorities: Involved in trade cases (USITC, USDOC) and local permitting processes (City of Fernandina Beach), influencing business operations and strategic project timelines.

Next Steps

• Engage in 2026 Cellulose Specialties pricing discussions, targeting a significant reset.
• Await preliminary determinations from the U.S. Department of Commerce in the HPDP trade case in the first half of 2026.
• Monitor and participate in discussions related to the renewal of the USMCA in July 2026.
• Make final investment decisions on Biomaterials projects in 2025 and early 2026.
• Continue to engage opportunistically with interested parties regarding the potential sale of the Paperboard and High-Yield Pulp businesses.
• Pursue available administrative and legal avenues regarding the denied site plan application for the Fernandina Beach bioethanol facility.
• Advance engineering and commercial planning for a potential bioethanol facility in Fernandina Beach, Florida.
• Work on permitting, engineering, and commercial agreements for crude tall oil (CTO) facilities in Jesup, Georgia, and Tartas, France.
• Evaluate financing options for the AGE (Altamaha Green Energy, LLC) project.
• Conduct due diligence with GranBio for a pilot-scale ethanol-to-jet plant at the Jesup site.
• Idle Paperboard production for three weeks during the fourth quarter to align inventory levels with demand and preserve cash flow.
• Idle one of two High-Yield Pulp production lines for three weeks during the fourth quarter to manage inventory and preserve cash flow.
• Host a conference call and live webcast on November 5, 2025, to discuss results.

Key Dates

Recommendation

The company reported mixed Q3 2025 results, with declining net sales and adjusted EBITDA, and negative year-to-date cash flow from operations. However, the net loss significantly improved, and management provided an optimistic outlook for Q4 2025 Adjusted Free Cash Flow and long-term EBITDA growth targets by 2027. Strategic initiatives in Biomaterials are progressing, but the planned sale of Paperboard and High-Yield Pulp businesses faces delays. The stock presents a speculative long-term growth opportunity based on its biomaterials strategy and cost reductions, but current operational headwinds and market uncertainties suggest a 'hold' until clearer signs of sustained operational improvement and successful execution of strategic initiatives emerge.

Keywords

Rayonier Advanced Materials, RYAM, Q3 2025 Earnings, SEC Filing, Cellulose Specialties, Biomaterials, Cellulose Commodities, Paperboard, High-Yield Pulp, Adjusted EBITDA, Free Cash Flow, Tariffs, Trade Case, Sustainability, Renewable Products, Forestry, Pulp and Paper